IBI397 + sintilimab

IBI397 + sintilimab refers to a combination therapy involving two agents. Sintilimab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with ligands and thereby enhancing T-cell mediated anti-tumor immune responses. It is developed by Innovent Biologics and Eli Lilly, and marketed under the brand name Tyvyt[1][4][6]. Sintilimab has been approved in China for relapsed or refractory classical Hodgkin lymphoma and is being investigated in multiple solid tumors, often in combination with chemotherapy or targeted therapies[5][8]. The specific identity of IBI397 is not confirmed from the provided sources; however, it appears to be an investigational agent likely developed by Innovent Biologics as part of their oncology pipeline.

Other names

anti-PD-1 monoclonal antibody IBI308anti-PD1 monoclonal antibody IBI308anti-PD 1 monoclonal antibody IBI308